{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:45:20Z","timestamp":1787795120730,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA233486"],"award-info":[{"award-number":["R01CA233486"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00262-020-02615-7","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T13:03:56Z","timestamp":1590671036000},"page":"2147-2155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["NKG2D-Fc fusion protein promotes antitumor immunity through the depletion of immunosuppressive cells"],"prefix":"10.1007","volume":"69","author":[{"given":"Po-Hao","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ssu-Hsueh","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jui","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Farmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6189-180X","authenticated-orcid":false,"given":"Max A.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9170-7797","authenticated-orcid":false,"given":"Chien-Fu","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"2615_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","volume":"22","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329\u2013360. https:\/\/doi.org\/10.1146\/annurev.immunol.22.012703.104803","journal-title":"Annu Rev Immunol"},{"key":"2615_CR2","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991\u2013998. https:\/\/doi.org\/10.1038\/ni1102-991","journal-title":"Nat Immunol"},{"key":"2615_CR3","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3324\/haematol.2017.184192","volume":"103","author":"M de Charette","year":"2018","unstructured":"de Charette M, Houot R (2018) Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy. Haematologica 103:1256\u20131268. https:\/\/doi.org\/10.3324\/haematol.2017.184192","journal-title":"Haematologica"},{"key":"2615_CR4","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/ijc.27784","volume":"132","author":"YC Lin","year":"2013","unstructured":"Lin YC, Mahalingam J, Chiang JM et al (2013) Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer. Int J Cancer 132:1341\u20131350. https:\/\/doi.org\/10.1002\/ijc.27784","journal-title":"Int J Cancer"},{"key":"2615_CR5","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1182\/blood-2006-02-002774","volume":"108","author":"M Beyer","year":"2006","unstructured":"Beyer M, Schultze JL (2006) Regulatory T cells in cancer. Blood 108:804\u2013811. https:\/\/doi.org\/10.1182\/blood-2006-02-002774","journal-title":"Blood"},{"key":"2615_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12:253\u2013268. https:\/\/doi.org\/10.1038\/nri3175","journal-title":"Nat Rev Immunol"},{"key":"2615_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nri1806","volume":"6","author":"W Zou","year":"2006","unstructured":"Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295\u2013307. https:\/\/doi.org\/10.1038\/nri1806","journal-title":"Nat Rev Immunol"},{"key":"2615_CR8","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1164\/rccm.201204-0636OC","volume":"186","author":"PH Feng","year":"2012","unstructured":"Feng PH, Lee KY, Chang YL et al (2012) CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. Am J Respir Crit Care Med 186:1025\u20131036. https:\/\/doi.org\/10.1164\/rccm.201204-0636OC","journal-title":"Am J Respir Crit Care Med"},{"key":"2615_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00432-009-0634-0","volume":"136","author":"CY Liu","year":"2010","unstructured":"Liu CY, Wang YM, Wang CL et al (2010) Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b\u2009+\/CD14(-)\/CD15\u2009+\/CD33\u2009+\u2009myeloid-derived suppressor cells and CD8\u2009+\u2009T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 136:35\u201345. https:\/\/doi.org\/10.1007\/s00432-009-0634-0","journal-title":"J Cancer Res Clin Oncol"},{"key":"2615_CR10","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1158\/0008-5472.CAN-12-4115","volume":"73","author":"Y Mao","year":"2013","unstructured":"Mao Y, Poschke I, Wennerberg E et al (2013) Melanoma-educated CD14\u2009+\u2009cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res 73:3877\u20133887. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-4115","journal-title":"Cancer Res"},{"key":"2615_CR11","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1084\/jem.20050715","volume":"202","author":"PC Rodriguez","year":"2005","unstructured":"Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB, Gilbert J, Ochoa AC (2005) Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 202:931\u2013939. https:\/\/doi.org\/10.1084\/jem.20050715","journal-title":"J Exp Med"},{"key":"2615_CR12","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/mi.2013.62","volume":"7","author":"M Scurr","year":"2014","unstructured":"Scurr M, Ladell K, Besneux M et al (2014) Highly prevalent colorectal cancer-infiltrating LAP(+) Foxp3(\u2212) T cells exhibit more potent immunosuppressive activity than Foxp3(+) regulatory T cells. Mucosal Immunol 7:428\u2013439. https:\/\/doi.org\/10.1038\/mi.2013.62","journal-title":"Mucosal Immunol"},{"key":"2615_CR13","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350\u20131355. https:\/\/doi.org\/10.1126\/science.aar4060","journal-title":"Science"},{"key":"2615_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/ITT.S32617","volume":"2012","author":"MK Srivastava","year":"2012","unstructured":"Srivastava MK, Zhu L, Harris-White M et al (2012) Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer. Immunotargets Ther. 2012:7\u201312. https:\/\/doi.org\/10.2147\/ITT.S32617","journal-title":"Immunotargets Ther."},{"key":"2615_CR15","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1002\/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO;2-1","volume":"32","author":"D Golgher","year":"2002","unstructured":"Golgher D, Jones E, Powrie F, Elliott T, Gallimore A (2002) Depletion of CD25\u2009+\u2009regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 32:3267\u20133275. https:\/\/doi.org\/10.1002\/1521-4141(200211)32:11%3c3267:AID-IMMU3267%3e3.0.CO;2-1","journal-title":"Eur J Immunol"},{"key":"2615_CR16","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1158\/0008-5472.CAN-10-3200","volume":"71","author":"T Zhang","year":"2011","unstructured":"Zhang T, Sentman CL (2011) Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res 71:2066\u20132076. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-3200","journal-title":"Cancer Res"},{"key":"2615_CR17","doi-asserted-by":"publisher","first-page":"e35141","DOI":"10.1371\/journal.pone.0035141","volume":"7","author":"TH Kang","year":"2012","unstructured":"Kang TH, Mao CP, He L, Tsai YC, Liu K, La V, Wu TC, Hung CF (2012) Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8\u2009+\u2009T cells in the tumor loci and enhanced anti-tumor effects. PLoS ONE 7:e35141. https:\/\/doi.org\/10.1371\/journal.pone.0035141","journal-title":"PLoS ONE"},{"key":"2615_CR18","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1158\/2326-6066.CIR-16-0234","volume":"5","author":"J Hu","year":"2017","unstructured":"Hu J, Bernatchez C, Zhang L, Xia X, Kleinerman ES, Hung MC, Hwu P, Li S (2017) Induction of NKG2D ligands on solid tumors requires tumor-specific CD8(+) T cells and histone acetyltransferases. Cancer Immunol Res 5:300\u2013311. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0234","journal-title":"Cancer Immunol Res"},{"key":"2615_CR19","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1084\/jem.20120565","volume":"209","author":"H Jung","year":"2012","unstructured":"Jung H, Hsiung B, Pestal K, Procyk E, Raulet DH (2012) RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry. J Exp Med 209:2409\u20132422. https:\/\/doi.org\/10.1084\/jem.20120565","journal-title":"J Exp Med"},{"key":"2615_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s12276-018-0130-1","volume":"50","author":"YJ Park","year":"2018","unstructured":"Park YJ, Kuen DS, Chung Y (2018) Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. Exp Mol Med 50:109. https:\/\/doi.org\/10.1038\/s12276-018-0130-1","journal-title":"Exp Mol Med"},{"key":"2615_CR21","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798\u2013809. https:\/\/doi.org\/10.1038\/nrc2734","journal-title":"Nat Rev Cancer"},{"key":"2615_CR22","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1158\/0008-5472.CAN-11-1792","volume":"72","author":"AM Lesokhin","year":"2012","unstructured":"Lesokhin AM, Hohl TM, Kitano S et al (2012) Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res 72:876\u2013886. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-1792","journal-title":"Cancer Res"},{"key":"2615_CR23","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00262-017-1988-9","volume":"66","author":"V Umansky","year":"2017","unstructured":"Umansky V, Blattner C, Gebhardt C, Utikal J (2017) CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma. Cancer Immunol Immunother 66:1015\u20131023. https:\/\/doi.org\/10.1007\/s00262-017-1988-9","journal-title":"Cancer Immunol Immunother"},{"key":"2615_CR24","first-page":"8360","volume":"63","author":"SC Robinson","year":"2003","unstructured":"Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR (2003) A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 63:8360\u20138365","journal-title":"Cancer Res"},{"key":"2615_CR25","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3389\/fimmu.2018.00398","volume":"9","author":"V Fleming","year":"2018","unstructured":"Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V (2018) Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front Immunol 9:398. https:\/\/doi.org\/10.3389\/fimmu.2018.00398","journal-title":"Front Immunol"},{"key":"2615_CR26","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1073\/pnas.1417320112","volume":"112","author":"E Romano","year":"2015","unstructured":"Romano E, Kusio-Kobialka M, Foukas PG et al (2015) Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci USA 112:6140\u20136145. https:\/\/doi.org\/10.1073\/pnas.1417320112","journal-title":"Proc Natl Acad Sci USA"},{"key":"2615_CR27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3389\/fonc.2014.00385","volume":"4","author":"MK Callahan","year":"2014","unstructured":"Callahan MK, Postow MA, Wolchok JD (2014) CTLA-4 and PD-1 Pathway Blockade: combinations in the Clinic. Front Oncol 4:385. https:\/\/doi.org\/10.3389\/fonc.2014.00385","journal-title":"Front Oncol"},{"key":"2615_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/77793","volume":"1","author":"A Diefenbach","year":"2000","unstructured":"Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH (2000) Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 1:119\u2013126. https:\/\/doi.org\/10.1038\/77793","journal-title":"Nat Immunol"},{"key":"2615_CR29","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1084\/jem.20051511","volume":"202","author":"F Ghiringhelli","year":"2005","unstructured":"Ghiringhelli F, Menard C, Terme M et al (2005) CD4\u2009+\u2009CD25\u2009+\u2009regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 202:1075\u20131085. https:\/\/doi.org\/10.1084\/jem.20051511","journal-title":"J Exp Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02615-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02615-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02615-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:01:50Z","timestamp":1622160110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02615-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["2615"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02615-7","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]},"assertion":[{"value":"24 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors do not declare any competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The housing and handling of mice follow guidelines established by Johns Hopkins Medical Institutions Animal Care and Use Committee and the National Institutes of Health. The Oncology Center Animal Facility has full-time veterinary support through the Department of Comparative Medicine. Animals are monitored daily for infection and other illnesses by trained animal technicians. The criteria include: infection, failure to thrive, perceived pain, respiratory distress, etc. Research support services include training classes and the capacity for full post-mortem analysis is available on request. Only trained laboratory personnel and animal technicians were allowed to handle laboratory animals. All individuals handling mice were registered to protocols at the Johns Hopkins Animal Care and Use Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}